Changes

Jump to: navigation, search

B-cell acute lymphoblastic leukemia - historical

2,367 bytes added, 14:05, 8 September 2019
m
Daunorubicin & Prednisone {{#subobject:aa10e0|Regimen=1}}
===References===
# Fernbach DJ, Sutow WW, Thurman WG, Vietti TJ. Clinical evaluation of cyclophosphamide: a new agent for the treatment of children with acute leukemia. JAMA. 1962 Oct 6;182:30-7. [https://jamanetwork.com/journals/jama/article-abstract/331608 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/13892445 PubMed]
 
==Daunorubicin, L-Asparaginase, Vincristine, Prednisone {{#subobject:8804f2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a6fef6|Variant=1}}===
{| class="wikitable" style="width: 50%; text-align:center;"
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198607313150501 Rivera et al. 1986]
|style="background-color:#91cf61"|Non-randomized
|-
|}
====Chemotherapy====
*[[Daunorubicin (Cerubidine)]]
*[[Asparaginase (Elspar)]]
*[[Vincristine (Oncovin)]]
*[[Prednisone (Sterapred)]]
 
'''4-week course'''
====Subsequent treatment====
*See paper for details of treatment beyond induction
 
===References===
# Rivera GK, Buchanan G, Boyett JM, Camitta B, Ochs J, Kalwinsky D, Amylon M, Vietti TJ, Crist WM. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. N Engl J Med. 1986 Jul 31;315(5):273-8. [https://www.nejm.org/doi/full/10.1056/NEJM198607313150501 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3523250 PubMed]
==Daunorubicin & Prednisone {{#subobject:aa10e0|Regimen=1}}==
===References===
# Holton CP, Vietti TJ, Nora AH, Donaldson MH, Stuckey WJ Jr, Watkins WL, Lane DM. Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia. N Engl J Med. 1969 Jan 23;280(4):171-4. [https://www.nejm.org/doi/full/10.1056/NEJM196901232800401 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/5248383 PubMed]
 
==L-Asparaginase, Vincristine, Prednisone {{#subobject:87ybf2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a61pz6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;"
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/6945911 Anderson et al. 1981]
| style="background-color:#1a9851" |Phase III (C)
|L-Asparaginase, Vindesine, Prednisone
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Asparaginase (Elspar)]]
*[[Vincristine (Oncovin)]]
*[[Prednisone (Sterapred)]]
 
===References===
# Anderson J, Krivit W, Chilcote R, Pyesmany A, Chard R, Hammond D. Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trial. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):1015-9. [https://www.ncbi.nlm.nih.gov/pubmed/6945911 PubMed]
==Pentostatin monotherapy {{#subobject:aa19e0|Regimen=1}}==
LookupUsers, editors, emailconfirmed
24,604
edits

Navigation menu